The Australian Competition and Consumer Commission today issued a statement of issues on the proposed acquisition of the consumer healthcare business of Pfizer Inc by Johnson & Johnson.
The statement of issues seeks further information on market definition and a number of competition issues which the ACCC has identified. Such competition issues primarily relate to the following product categories: worm treatments, anti-diarrhoeals, anti-allergics and nicotine replacement therapy products.
The ACCC invites further submissions from the market focused on these matters by Monday, 11 December 2006. The ACCC anticipates announcing its final decision on the proposed acquisition on 20 December 2006. The Statement of Issues will be available on the ACCC website shortly.